Home   中文简体 中文繁體 
Company News Products R&D Investor relationship Human Resource Contact Us
 
 
 
News
 
News
  • 2014 Enviroment Report 2015-04-02 16:50
  • 2013 Enviroment Report 2014-03-31 16:27
  • Fudan-Zhangjiang Successful Listing on the Main Board of HKEx 2013-12-18 15:52
  • The Success of the Initiation of Marketing of FMD® (Hemoporfin) 2013-12-16 14:04
  • Honor rewarded again for FDZJ 2013-08-27 12:05
  • The company’s product “Aminolevulinic Acid Hydrochloride (ALA ®)” has been granted award of “the Top 100 Shanghai High-tech Achievement Transformation Project in 2011” 2012-07-31 11:41
  • A strategic cooperation agreement on innovative drug research and development (r&d) was signed between Shanghai Medical Group and Shanghai Fudan-Zhangjiang 2011-02-24 15:52
  • Mr. Sheng Xiaoming, the vice mayor visited FDZJ as an inspection and investigation 2009-02-27
  • Member of the Standing Committee of the CPC Shanghai Committee， secretary of the CPC Pudong New District Committee Xu Lin and other government officers visited our company to investigate the status of the research and development of innovative drugs 2008-09-13
  • FDZJ registered and constructed FDZJ’s Taizhou Pharmaceutical Limited Company with the name of "Taizhou Medicine", a subsidiary located in Taizhou City, Jiangsu Province 2007-3-27
  • The Permission for Clinical Trial for Nifeviroc, a New Drug (Class 1.1), was Issued. 2007-3-22
  • Beixi®, Down’s Screening System, obtains the support of “National Torch Plan” 2007-2-22
  • Licenses for Aminolevulinic acid （ALA） Issued by SFDA in Feb. 2007 and Sales Started in May, 2007 2007-2-14
  • FDZJ’s Project of “The Clinical Study of the Treatment of Port Wine Stain (naevus flammeus) by Hemoporfin” was Selected by “Mountaineering Project” Sponsored by Science and Technology Committee of Shanghai 2006-9-30
  • FDZJ’s Project of The R & D of Innovative Photodynamic Drugs and Industrialization” Supported by “Clear-sighting Plan” Sponsored by Pudong New District 2005-12-29
  • FDZJ’s Project of “R & D and Industrialization for the Targeting Drugs for Tumor Therapy and Hyperplasia Therapy” was listed in the “Beadroll of Key R & D Project for Shanghai’s Development base on Science and Technology” 2005-12-27
  • Class 1 New Drug Duteroporphyrin Listed in the “Beadroll of Key R & D Project” Sponsored by Science and Technology Committee. 2005-10-18
  • The Delegation of IPSEN, A World Well-known Pharmaceutical Company, Led by the President, CEO, Mr. Jean-Luc Bulingard, Visited FDZJ 2004-11-27
  • The Leaders of Pudong New District and Leader of Science and Technology Bureau of Pudong New District Visited FDZJ and Gave Instructions on Further Development 2004-11-23
  • FDZJ attended the "10th Congress,Asian-Pacific Association for Laser Medicine and Surgery"and successfully held a special meeting on Photodynamic Drug Therapy (PDT) and a PDT Forum 2004-11-09
    • Page: 2/3  Per Page20  Total 45  No.: [1][2][3]
    Links  |  SiteMap  |  Privacy Copyright© Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. 2007
    （沪）-非经营性-2024-0273    沪ICP备10027510号-1